Universal reference book for medicines
Name of the drug: RETABOLIL (RETABOLIL)

Active substance: nandrolone

Type: Anabolic steroid for systemic use - depot form

Manufacturer: GEDEON RICHTER (Hungary)
Composition, form of production and packaging
Solution for the / m introduction oily
greenish-yellow color, transparent, with a characteristic odor, without extraneous visible mechanical inclusions.

1 ml

nandrolone decanoate 50 mg

[PRING] benzyl alcohol, isopropyl alcohol, sunflower oil.

1 ml - ampoules (1) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Retabolil is a synthetic derivative of testosterone, an anabolic drug of prolonged action (depot preparation).
Stimulates the synthesis of protein in the body, causes a delay in nitrogen, calcium, sodium, potassium, chlorides and phosphorus, which leads to an increase in muscle mass and accelerated bone growth, water retention in the body. Has low androgenic activity.
PHARMACOKINETICS

Nandrolone decanoate is slowly released from the injection site into the bloodstream with T 1/2 6 days.
In the blood, the ether rapidly hydrolyzes into nandrolone with T 1/2 less than 1 hour. In general, T 1/2 for the combined process of hydrolysis, distribution and excretion of nandrolone from plasma is 4.3 h. Nandrolone is metabolized in the liver. Metabolites excreted by the kidneys are 19-norandosterone, 19-norethiocholanone and 19-norepiantrosterone. Data on the pharmacological activity of these metabolites are not known.
INDICATIONS

Use strictly according to the doctor's prescription to avoid complications.

Diseases in which prolonged use of anabolic agents is necessary:

osteoporosis of various genesis;

- cachexia of various etiologies;

- Violation of protein metabolism after severe burns, injuries, surgical operations, radiation therapy, with severe infectious diseases;

- progressive muscular dystrophy;

- Spinal amyotrophy of Verdnig-Hoffmann;

- diabetic retinopathy;

- Disseminated breast cancer in women (as a palliative method of treatment);

- glomerulonephritis, program hemodialysis in patients with chronic renal failure.

Retabolil can be used in combination therapy with glucocorticoids, tuberculostatic and cytostatic drugs.

DOSING MODE

Retabolil can be prescribed for both inpatient and outpatient patients.
The drug is injected deep in the / m. The dose of the drug is determined individually. The average single dose for adults is 25-50 mg every 3-4 weeks. With myopathies, individual doses can be set. In severe renal failure, the dose is 50 mg weekly. Oncological patients can be administered at a dose of 50 mg every 5 days.
To children Retabolil is prescribed in a dose of 400 mkg / kg of body weight every 3-4 weeks.

SIDE EFFECT

In patients of both sexes: nausea, loss of appetite, vomiting, burning sensation in the tongue, increased or decreased libido, acne (especially in women and puberty boys).
There may be a delay in nitrogen, sodium and water in the body, swelling, cholestasis, jaundice, increased vascularization of the skin, hypercalcemia (especially in immobile patients and in women with metastases of breast cancer).
Suppression of gonadotropin secretion.

In women: symptoms of virilization (hirsutism, alopecia, irreversible decrease in the tone of the voice, irregular menstruation, suppression of ovarian function, an increase in the clitoris).

In men: suppression of testicles, oligospermia, gynecomastia, penis enlargement, frequent erections at pubertal age.

CONTRAINDICATIONS

- nephrotic syndrome;

- prostate cancer;

- Acute or chronic prostatitis;

- breast cancer in men;

- severe liver damage, liver failure in cancer patients or metastases to the liver;

- Pregnancy and the period of breastfeeding;

- Hypersensitivity to any of the components of the drug.

PREGNANCY AND LACTATION

The drug is contraindicated for use during pregnancy and during breastfeeding.

APPLICATION FOR FUNCTIONS OF THE LIVER

The drug is administered with caution to patients with renal insufficiency.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

The drug is contraindicated for use in severe liver damage, with liver failure in cancer patients or in patients with liver metastases.

In some cases, against the background of the use of the drug, there are violations of the indices of some functional liver samples.
Therefore, every 4 weeks, liver function should be monitored.
APPLICATION FOR CHILDREN

In connection with the androgenic activity of children, the drug is prescribed in the event that the anticipated benefit exceeds the potential risk.
With the use of Retabolil in high doses at pubertal age, premature closure of the growth zones and the suspension of growth are possible.
APPLICATION IN ELDERLY PATIENTS

Data on the use of Retabolil in elderly patients are not provided.

SPECIAL INSTRUCTIONS

To achieve the optimal therapeutic effect against Retabolil therapy, the patient should receive adequate amounts of protein, fat, carbohydrates, vitamins, minerals with food.

In connection with androgenic activity of women and children, the drug is prescribed if the intended benefit exceeds the potential risk.

With the use of Retabolil in high doses at pubertal age, premature closure of the growth zones and the suspension of growth are possible.

With caution, the drug should be used for cardiac, renal failure, arterial hypertension, migraine, epilepsy, glaucoma (or in the presence of them in history), because anabolic steroids cause sodium and fluid retention in the body.
During treatment with Retabolil, careful monitoring of intraocular pressure should be performed.
Before and during the treatment with the drug, rectal control of the size of the prostate gland is necessary.

In some cases, against the background of the use of the drug, there are violations of the indices of some functional liver samples.
Therefore, every 4 weeks, liver function should be monitored.
In patients with diabetes, Retabolil may cause an increase in glucose tolerance, thereby reducing the need for insulin or oral hypoglycemic agents.

In patients with metastases of breast cancer in the bone, hypercalcemia may develop.
In this case, therapy with anabolic steroids can be prescribed only after the normalization of the level of calcium in the blood.
The use of anabolic steroids for the purpose of stimulating athletic qualities can cause serious damage to health and is unacceptable!

OVERDOSE

Symptoms: Increased side effects described.

Conduct symptomatic therapy.
There is no specific antidote. In the case of signs of virilization, the withdrawal of the drug is indicated.
DRUG INTERACTION

With care, prescribe Retabolil against the backdrop of the use of anticoagulants of indirect action (possibly strengthening their action), hypoglycemic drugs (possibly increasing their hypoglycemic effect).

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

Storage conditions:

Store at 15-30 В° C, out of the reach of children.

The solution of Retabolil under the influence of cold can become turbid.
In this case, before use, the ampoule with the preparation must be heated to dissolve the crystals.
Shelf life:

5 years.

Do not use the product after the expiry date indicated on the package.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!